

6 January 2023

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.

Subject: Disclosure of Material Information – Approval of Name Change

Dear Sir / Madam,

This is with reference to section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of PSX Limited Regulations. The Company hereby conveys the following material information:

The name of the Company has been changed to Haleon Pakistan Limited and a Certificate of Incorporation on Change of Name has been issued by the Securities and Exchange Commission of Pakistan in this respect dated 3 January 2023.

The name "Haleon Pakistan Limited" shall be accompanied by the phrase "Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited" in parenthesis as prescribed under section 13 of the Companies Act, 2017.

This shall have no effect on the principal line of business of the Company. The disclosure form in terms of Section 96 of the Securities Act, 2015 is also attached.

You may please inform the TRE Certificate holders of the Exchange accordingly

Yours truly,

For and on Behalf of Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited)



Ms. Mashal Mohammad
Company Secretary

CC: Executive Director / HOD,
Offsite-II Department, Supervision Division,
Securities and Exchange Commission of Pakistan,
63, NIC Building, Jinnah Avenue, Blue Area, Islamabad.

**SCHEDULE
DISCLOSURE FORM**

Name of Company: Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited)
Registered Office: Sandoz Nagar, Petaro Road, Jamshoro Sindh, 76100.
Date of Report: 6 January 2023
Contact Information: Mashal Mohammad
Company Secretary
Telephone No.: +92-111-475-725
Fax No.: N/A
Email Address: pakistan.shareinfo@haleon.com

Disclosure of price sensitive information by listed company in terms of Section 96 of the Securities Act 2015.

The name of the Company has been changed to Haleon Pakistan Limited and a Certificate of Incorporation on Change of Name has been issued by the Securities and Exchange Commission of Pakistan in this respect dated 3 January 2023.

The name "Haleon Pakistan Limited" shall be accompanied by the phrase "Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited" in parenthesis as prescribed under section 13 of the Companies Act, 2017.

This shall have no effect on the principal line of business of the Company.

For and on Behalf of Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited)



Ms. Mashal Mohammad
Company Secretary